# Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone

Study · id `cardio:ct-nct01529541` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01529541](<https://clinicaltrials.gov/study/NCT01529541>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01529541

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It plans to enroll 200 participants.

## Technical summary

Registry record NCT01529541. Randomized; triple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2013-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT01529541, source copy `cardio:ctgov-nct01529541-2014-05-14`, retrieved 2026-10-26)
- Start date: 2011-05 (registry gives no type) (ClinicalTrials.gov record NCT01529541, source copy `cardio:ctgov-nct01529541-2014-05-14`, retrieved 2026-10-26)
- Primary completion: 2013-05 (actual) (ClinicalTrials.gov record NCT01529541, source copy `cardio:ctgov-nct01529541-2014-05-14`, retrieved 2026-10-26)
- Completion: 2013-10 (actual) (ClinicalTrials.gov record NCT01529541, source copy `cardio:ctgov-nct01529541-2014-05-14`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT01529541, source copy `cardio:ctgov-nct01529541-2014-05-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01529541-2014-05-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone
- Acronym: CWP-DIANA-302
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): Anagliptin
- Intervention (Drug): Sitagliptin
- Lead sponsor: JW Pharmaceutical
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: JW Pharmaceutical (`cardio:org-jw-pharmaceutical`)

## Provenance

Content hash: b532d72675c581d7ec6cd0e64eae5c010bce171ee76c4f9965fa3c1483ba2c2c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
